Chronic obstructive pulmonary disease (COPD)
Evidencia
Esta página contiene una instantánea del contenido destacado que pone de relieve las evidencias que abordan cuestiones clínicas fundamentales, incluidas las áreas de incertidumbre. Consulte la lista de referencias del tema principal para conocer todas las fuentes en las que se basa este tema.
Tablas de evidencia del BMJ Best Practice
Las tablas de evidencia proporcionan capas de evidencia de fácil navegación en el contexto de preguntas clínicas específicas, utilizando GRADE y una clasificación de eficacia de las BMJ Best Practice. Siga los enlaces de la parte inferior de la tabla, que van a la puntuación de la evidencia relacionada en el texto del tema principal, proporcionando un contexto adicional para la pregunta clínica. Conozca más sobre nuestras tablas de evidencia.
Esta tabla es un resumen del análisis reportado en una Respuesta Clínica Cochrane que se centra en la pregunta clínica más importante antes mencionada.
Confidence in the evidence is high or moderate to high where GRADE has been performed and the intervention is more effective/beneficial than the comparison for key outcomes.
Población: Adults with COPD
Intervención: IDM ᵃ
Comparación: Usual care (regular follow-up visits with healthcare providers)
| Resultado | Eficacia (clasificación BMJ)? | Confianza en las evidencias (GRADE)? |
|---|---|---|
Quality of life (>6 to 15 months): St. George’s Respiratory Questionnaire (SGRQ) ᵇ | Favors intervention | Moderate |
Functional exercise capacity (>6 to 15 months) | Favors intervention | Moderate |
Respiratory‐related hospital admissions (12 months) | Favors intervention | High |
All hospital admissions | Favors intervention | Moderate |
Hospital days per patient (all causes) | Favors intervention | Moderate |
Emergency Department visits | Favors intervention | Moderate |
Number of patients experiencing ≥ 1 exacerbation | No statistically significant difference | GRADE assessment not performed for this outcome |
Mortality | No statistically significant difference | GRADE assessment not performed for this outcome |
Need for at least one course of oral steroids | No statistically significant difference | GRADE assessment not performed for this outcome |
Need for at least one course of antibiotics | No statistically significant difference | GRADE assessment not performed for this outcome |
Nota The Cochrane review which underpins this Cochrane Clinical Answer (CCA) notes that the effects of IDM are better in the short and medium term, and that the effect size was different between included studies and interventions. IDM should be carefully designed and evaluated, consisting of different components which are linked to the personal goals of the patient. ᵃ Including organizational, professional, patient-directed, and financial interventions in primary, secondary, and tertiary healthcare settings. See CCA and the underlying Cochrane review for more information on specific interventions and the dominant components of the IDM programs. ᵇ Although statistically significant, this result did not quite reach the minimum clinically important difference. The CCA also reports a subgroup analysis for quality of life measured by the Chronic Respiratory Questionnaire. However, this was only reported in two studies and the analysis was underpowered.
Esta tabela de evidências está relacionada às seguintes seções:
Esta tabela é um sumário da análise relatada em uma Resposta Clínica Cochrane que enfoca a importante questão clínica acima.
Confidence in the evidence is high or moderate to high where GRADE has been performed and the intervention is more effective/beneficial than the comparison for key outcomes.
População: Adults with moderate-to-severe COPD
Intervenção: Umeclidinium (once daily via a dry powder inhaler for 12-52 weeks)
Comparação: Placebo
| Desfecho | Eficácia (classificação do BMJ)? | Confiança na evidência (GRADE)? |
|---|---|---|
Number of participants with exacerbations requiring corticosteroids, antibiotics, or both at 52 weeks | Favors intervention | High |
Quality of life at 24-52 weeks (measured by the St George's Respiratory Questionnaire [SGRQ]) | Favors intervention | Moderate |
Number of participants with hospital admissions due to COPD exacerbation at 52 weeks (measured by the Transitional Dyspnea Index [TDI]) | No statistically significant difference | Low |
Improvement in symptoms at 24 weeks | Favors intervention | High |
Lung function at 4-52 weeks | Favors intervention | High |
Nonfatal serious adverse events | No statistically significant difference | Moderate |
Adverse events | No statistically significant difference | Moderate |
Esta tabela de evidências está relacionada às seguintes seções:
Respostas Clínicas Cochrane
As Respostas Clínicas Cochrane (RCCs) proporcionam um ponto de entrada amigável, digerível e clinicamente focado para as pesquisas rigorosas das revisões sistemáticas Cochrane. Elas são desenvolvidas para serem acionáveis e para respaldar a tomada de decisão no local de atendimento, e foram adicionadas a seções relevantes do texto principal do Best Practice.
- What are the effects of integrated disease management (IDM) interventions for people with chronic obstructive pulmonary disease (COPD)?
- How does tiotropium compare with ipratropium bromide for people with chronic obstructive pulmonary disease (COPD)?
- How does umeclidinium bromide compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
- How does a combined inhaler with once‐daily long‐acting beta2‐agonist (LABA) plus a long‐acting muscarinic antagonist (LAMA) compare with placebo for adults with chronic obstructive pulmonary disease (COPD)?
- How does long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?
- What are the benefits and harms of inhaled corticosteroids (ICS) in people with stable chronic obstructive pulmonary disease (COPD)?
- What are the effects of long‐acting inhaled therapies for adults with chronic obstructive pulmonary disease (COPD)?
- How do phosphodiesterase‐4 inhibitors compare with placebo for people with chronic obstructive pulmonary disease?
- What are the effects of prophylactic antibiotics for people with chronic obstructive pulmonary disease (COPD)?
- Which interventions lead to increased regular physical activity for people with chronic obstructive pulmonary disease (COPD)?
- For people with chronic bronchitis or chronic obstructive pulmonary disease, how do mucolytic agents compare with placebo?
- What are the effects of pulmonary rehabilitation after exacerbation in people with chronic obstructive pulmonary disease?
- For people with chronic obstructive pulmonary disease (COPD), what are the effects of a supervised maintenance program after pulmonary rehabilitation?
- How does bronchoscopic lung volume reduction compare with medical therapy in people with chronic obstructive pulmonary disease?
- What are the effects of influenza vaccine in people with chronic obstructive pulmonary disease (COPD)?
- How do statins compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
- How does lung volume reduction surgery compare with usual medical care in people with diffuse emphysema?
O uso deste conteúdo está sujeito ao nosso aviso legal